iBio (IBIO)
Market Price (2/7/2026): $2.31 | Market Cap: $122.4 MilSector: Health Care | Industry: Biotechnology
iBio (IBIO)
Market Price (2/7/2026): $2.31Market Cap: $122.4 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -36% | Weak multi-year price returns3Y Excs Rtn is -151% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4089% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 186% | Expensive valuation multiplesP/SPrice/Sales ratio is 256x | |
| Stock price has recently run up significantly6M Rtn6 month market price return is 307% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 288% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3451%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3460% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 761% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20% | ||
| High stock price volatilityVol 12M is 140% | ||
| Key risksIBIO key risks include [1] a history of significant losses and negative cash flow that raises going-concern doubts, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -36% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 186% |
| Weak multi-year price returns3Y Excs Rtn is -151% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4089% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 256x |
| Stock price has recently run up significantly6M Rtn6 month market price return is 307% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 288% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3451%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3460% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 761% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20% |
| High stock price volatilityVol 12M is 140% |
| Key risksIBIO key risks include [1] a history of significant losses and negative cash flow that raises going-concern doubts, Show more. |
Qualitative Assessment
AI Analysis | Feedback
iBio (IBIO) stock has gained about 50% since 10/31/2025 because of the following key factors:
1. Positive Preclinical Data for IBIO-610 in Obesity and Cardiometabolic Diseases.
iBio announced promising non-human primate (NHP) data for its Activin E antibody candidate, IBIO-610, on November 12, 2025. The data indicated a predicted human half-life of up to 100 days, suggesting the potential for infrequent, twice-yearly dosing for the treatment of obesity and cardiometabolic diseases. These findings also supported a differentiated mechanism enabling fat-selective, GLP-1–synergistic weight loss with muscle preservation. The positive results were presented at ObesityWeek® 2025 and PEGS Europe.
2. Successful Capital Raises to Fund Pipeline Development.
The company strengthened its financial position through two significant capital raises. In November 2025, iBio completed an underwritten public offering of pre-funded warrants and common warrants with the potential for up to $100 million in gross proceeds, extending its cash runway into the fourth quarter of fiscal year 2027. Subsequently, in January 2026, iBio secured approximately $26 million in private placement financing from existing healthcare-focused institutional investors. This funding is specifically earmarked to advance its preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and bispecific programs, further extending its cash runway into calendar 2028.
Show more
1. Positive Preclinical Data for IBIO-610 in Obesity and Cardiometabolic Diseases.
iBio announced promising non-human primate (NHP) data for its Activin E antibody candidate, IBIO-610, on November 12, 2025. The data indicated a predicted human half-life of up to 100 days, suggesting the potential for infrequent, twice-yearly dosing for the treatment of obesity and cardiometabolic diseases. These findings also supported a differentiated mechanism enabling fat-selective, GLP-1–synergistic weight loss with muscle preservation. The positive results were presented at ObesityWeek® 2025 and PEGS Europe.
2. Successful Capital Raises to Fund Pipeline Development.
The company strengthened its financial position through two significant capital raises. In November 2025, iBio completed an underwritten public offering of pre-funded warrants and common warrants with the potential for up to $100 million in gross proceeds, extending its cash runway into the fourth quarter of fiscal year 2027. Subsequently, in January 2026, iBio secured approximately $26 million in private placement financing from existing healthcare-focused institutional investors. This funding is specifically earmarked to advance its preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and bispecific programs, further extending its cash runway into calendar 2028.
Show more
Stock Movement Drivers
Fundamental Drivers
The 51.2% change in IBIO stock from 10/31/2025 to 2/6/2026 was primarily driven by a 345.5% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.60 | 2.42 | 51.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 25.0% |
| P/S Multiple | 57.6 | 256.4 | 345.5% |
| Shares Outstanding (Mil) | 14 | 53 | -72.8% |
| Cumulative Contribution | 51.2% |
Market Drivers
10/31/2025 to 2/6/2026| Return | Correlation | |
|---|---|---|
| IBIO | 51.2% | |
| Market (SPY) | 1.3% | 24.2% |
| Sector (XLV) | 9.3% | -4.6% |
Fundamental Drivers
The 255.9% change in IBIO stock from 7/31/2025 to 2/6/2026 was primarily driven by a 1333.9% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.68 | 2.42 | 255.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 33.3% |
| P/S Multiple | 17.9 | 256.4 | 1333.9% |
| Shares Outstanding (Mil) | 10 | 53 | -81.4% |
| Cumulative Contribution | 255.9% |
Market Drivers
7/31/2025 to 2/6/2026| Return | Correlation | |
|---|---|---|
| IBIO | 255.9% | |
| Market (SPY) | 9.6% | 16.5% |
| Sector (XLV) | 21.5% | 3.6% |
Fundamental Drivers
The -19.6% change in IBIO stock from 1/31/2025 to 2/6/2026 was primarily driven by a -83.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.01 | 2.42 | -19.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 185.7% |
| P/S Multiple | 148.5 | 256.4 | 72.7% |
| Shares Outstanding (Mil) | 9 | 53 | -83.7% |
| Cumulative Contribution | -19.6% |
Market Drivers
1/31/2025 to 2/6/2026| Return | Correlation | |
|---|---|---|
| IBIO | -19.6% | |
| Market (SPY) | 15.8% | 17.7% |
| Sector (XLV) | 8.8% | 20.9% |
Fundamental Drivers
The -83.4% change in IBIO stock from 1/31/2023 to 2/6/2026 was primarily driven by a -99.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312023 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.60 | 2.42 | -83.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 0 | -72.2% |
| P/S Multiple | 3.6 | 256.4 | 7051.0% |
| Shares Outstanding (Mil) | 0 | 53 | -99.2% |
| Cumulative Contribution | -83.4% |
Market Drivers
1/31/2023 to 2/6/2026| Return | Correlation | |
|---|---|---|
| IBIO | -83.4% | |
| Market (SPY) | 76.2% | 11.0% |
| Sector (XLV) | 23.8% | 13.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IBIO Return | -48% | -97% | -85% | 79% | -21% | 11% | -100% |
| Peers Return | -47% | -50% | 21% | -33% | 9% | -3% | -77% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| IBIO Win Rate | 42% | 25% | 33% | 50% | 50% | 100% | |
| Peers Win Rate | 31% | 37% | 50% | 37% | 55% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| IBIO Max Drawdown | -48% | -97% | -87% | -23% | -77% | -3% | |
| Peers Max Drawdown | -52% | -62% | -43% | -48% | -38% | -14% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ABCL, RXRX, SDGR, RLAY, TWST. See IBIO Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/6/2026 (YTD)
How Low Can It Go
| Event | IBIO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -99.9% | -25.4% |
| % Gain to Breakeven | 111693.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -83.6% | -33.9% |
| % Gain to Breakeven | 510.5% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -97.9% | -19.8% |
| % Gain to Breakeven | 4670.6% | 24.7% |
| Time to Breakeven | 236 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -94.7% | -56.8% |
| % Gain to Breakeven | 1804.8% | 131.3% |
| Time to Breakeven | 604 days | 1,480 days |
Compare to ABCL, RXRX, SDGR, RLAY, TWST
In The Past
iBio's stock fell -99.9% during the 2022 Inflation Shock from a high on 2/9/2021. A -99.9% loss requires a 111693.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About iBio (IBIO)
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
AI Analysis | Feedback
Moderna for plant-based biologics.
AI Analysis | Feedback
- Fibrosis Therapeutics: Developing biologic drug candidates like IBIO-101 for the treatment of fibrotic diseases such as systemic scleroderma.
- Oncology Therapeutics: Researching and developing novel therapeutic candidates for cancer leveraging an AI-powered discovery platform.
- Vaccine Candidates: Utilizing their proprietary plant-based platform for the rapid development of vaccine candidates.
- Biopharmaceutical CDMO Services: Offering contract development and manufacturing services to other companies using their proprietary *FastPharming* plant-based expression system for biologics.
AI Analysis | Feedback
iBio (symbol: IBIO) primarily operates in a business-to-business (B2B) model, providing contract development and manufacturing organization (CDMO) services and engaging in research and development collaborations within the biopharmaceutical industry.
Based on iBio's public financial disclosures (e.g., 10-K filings), no single customer has accounted for 10% or more of the company's total revenue in recent fiscal years. As such, iBio does not publicly disclose specific names of individual major customers as per SEC regulations. This indicates a diversified customer base within its B2B operations.
Therefore, while specific customer company names are not publicly available due to revenue diversification, iBio's customers generally fall into the following categories:
- Biopharmaceutical Companies: This category encompasses a wide range of companies, from small, emerging biotechnology startups focused on drug discovery and development to larger, established pharmaceutical companies. These customers typically engage iBio for its FastPharming® platform to develop and manufacture biologics, including antibodies, vaccines, and other protein-based therapeutics for preclinical and clinical trials.
- Academic and Research Institutions: Universities, medical centers, and other non-profit research organizations often collaborate with iBio for specialized protein production, process development, and manufacturing services to advance their research programs and early-stage drug candidates.
- Government Agencies and NGOs: Occasionally, government bodies or non-governmental organizations may contract with iBio for specific research, development, or manufacturing projects, particularly in areas related to public health initiatives, infectious diseases, or biodefense.
AI Analysis | Feedback
null
AI Analysis | Feedback
Martin B. Brenner, Chief Executive Officer and Chief Scientific Officer
Dr. Brenner has a strong history of success leading drug discovery and development teams at several prominent pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. He most recently served as the Chief Scientific Officer at Pfenex Inc., a company that developed therapeutic equivalents, vaccines, biologics, and biosimilars using its patented technology, which was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020. Dr. Brenner was appointed interim CEO of iBio in January 2023 and became the permanent CEO in June 2023.
Felipe Duran, Chief Financial Officer
Mr. Duran previously served as iBio's Vice President of Financial Planning and Analysis (FP&A) from April 2021 to February 2023. From 2016 to 2021, he held the position of Executive Director (CFO) of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, where he significantly increased regional net sales through robust commercial pricing strategies and led the subsidiary to become an EBITDA-positive business. His prior experience also includes various strategy roles at Teva Pharmaceuticals and working as an FP&A Manager for Bupa and Noven Pharmaceuticals. Mr. Duran was appointed interim CFO in February 2023 and permanently assumed the role in June 2023.
Marc Banjak, Chief Legal Officer
Mr. Banjak brings over 15 years of experience in the biotechnology and contract research industries to iBio. He previously served as the first general counsel for both Istari Oncology and Dova Pharmaceuticals, and at Dova, he provided legal and compliance guidance through key milestones, including its acquisition by Swedish Orphan Biovitrum AB.
Kristi Sarno, Senior Vice President of Business Development
Ms. Sarno began her tenure as the Senior Vice President of Business Development in 2024.
AI Analysis | Feedback
Here are the key risks to iBio's business:- Financial Health and Going Concern: iBio has a history of significant losses and negative cash flow, requiring continuous external financing to fund its operations and research and development efforts. The company reported a consolidated net loss of $65.0 million for the fiscal year ended June 30, 2023. Its operating margin is substantially negative at -4089.4%. The company consistently relies on issuing new stock and warrants to raise capital, indicating a potential ongoing concern regarding its ability to generate sufficient revenue to sustain operations independently.
- Product Development and Commercialization Risk: As a biotechnology company, iBio's success is heavily dependent on its ability to successfully develop, obtain regulatory approvals for, and commercialize its product candidates. The generation of significant revenue is contingent on numerous factors, including setting acceptable product prices, securing adequate reimbursement, establishing effective sales, marketing, manufacturing, and distribution systems, achieving broad market acceptance, and protecting its intellectual property portfolio. There are inherent risks and uncertainties in the development and manufacturing of these product candidates, making the prediction of future revenue generation uncertain. Concerns have also been raised regarding slow pipeline progress.
- Shareholder Dilution: Directly linked to its funding needs, iBio's strategy of raising capital through the issuance of new shares and warrants poses a significant risk of dilution for existing shareholders. The company has a substantial number of stock options outstanding, which represent future potential dilution if exercised. This ongoing dilution is a necessary measure to fund expensive research and development but can reduce the ownership percentage and value of existing shares.
AI Analysis | Feedback
One clear emerging threat to iBio (IBIO) is the rapid advancement and potential industrial scalability of Cell-Free Protein Synthesis (CFPS) technologies.
CFPS systems offer a paradigm shift in protein manufacturing by producing proteins outside of living cells. These systems promise significantly faster development timelines, simpler purification processes, and potentially lower costs compared to traditional cell-based expression systems, including iBio's proprietary plant-based FastPharming platform. While CFPS technologies are still maturing for large-scale production of complex biologics, ongoing advancements in yield, efficiency, and platform engineering by various academic institutions and biotech companies (such as Arbor Biosciences and others exploring industrial applications) pose a direct competitive threat. Should CFPS platforms become robust, high-yield, and cost-effective for large-scale manufacturing of therapeutic proteins, they could undermine the speed, flexibility, and cost advantages that iBio currently promotes for its unique plant-based manufacturing solution across various applications, including vaccines and antibody production.
AI Analysis | Feedback
iBio (IBIO) focuses on developing biopharmaceutical products and providing contract development and manufacturing organization (CDMO) services. Their main product areas include immuno-oncology, fibrotic diseases, and cardiometabolic diseases, particularly obesity, leveraging their proprietary antibody discovery platform and FastPharming® System.
Addressable Markets:
- Immuno-Oncology: The global immuno-oncology market was estimated at USD 43.73 billion in 2023 and is projected to reach approximately USD 284.29 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 23.12% from 2024 to 2033. A broader global oncology market was valued at USD 234.6 billion in 2023 and is anticipated to reach USD 533.2 billion by 2032, with a CAGR of 9.6%. More specifically, the global cancer biologics market was USD 110.91 billion in 2024 and is projected to reach USD 232.02 billion by 2034, with a CAGR of 7.66%.
- Fibrotic Diseases (specifically Idiopathic Pulmonary Fibrosis - IPF): The global fibrotic diseases treatment market is expected to grow from USD 5.79 billion in 2024 to USD 10.35 billion by 2032, at a CAGR of 7.6%. The global idiopathic pulmonary fibrosis (IPF) treatment market was valued at USD 4.103.66 million in 2024 and is expected to reach USD 7.315.80 million by 2033, exhibiting a CAGR of 6.30% during 2025-2033. North America currently holds a significant share of this market, with the United States accounting for 88.2% of the North American IPF treatment market in 2024.
- Rare Diseases: The global rare diseases treatment market was valued at USD 224.30 billion in 2024 and is projected to reach USD 527.05 billion by 2034, with an expected CAGR of 8.92% from 2025 to 2034. North America dominated this market with a 49% revenue share in 2024. The U.S. rare diseases treatment market alone was estimated at USD 76.93 billion in 2024 and is predicted to be around USD 184.68 billion by 2034, growing at a CAGR of 9.15% from 2025 to 2034.
- Contract Development and Manufacturing Organization (CDMO) Services: The global CDMO market size was valued at USD 238.92 billion in 2024 and is projected to grow to USD 465.24 billion by 2032, exhibiting a CAGR of 9.0%. North America held the largest share of this market, at 38.59% (USD 92.22 billion) in 2024. Focusing on biologics, the global biologics CDMO market reached USD 25.32 billion in 2025 and is forecast to attain USD 36.51 billion by 2030, advancing at a 7.59% CAGR. North America controlled 34.54% of the biologics CDMO market share in 2024.
AI Analysis | Feedback
iBio (IBIO) is poised for potential revenue growth over the next 2-3 years, driven primarily by advancements in its preclinical pipeline and strategic initiatives in precision antibody therapies. The key drivers include:
- Advancement and Potential Commercialization of Lead Cardiometabolic and Obesity Candidates: iBio is heavily focused on its cardiometabolic and obesity pipeline, with lead candidates IBIO-610 (an Activin E-targeting antibody) and IBIO-600 (a long-acting anti-myostatin antibody). Preclinical data for IBIO-610 has demonstrated a 26% fat mass reduction without lean mass loss in mice, while IBIO-600 has shown extended half-life and dose-dependent muscle growth in non-human primates. The company aims to move these candidates into clinical investigation, with plans for obesity and cardiometabolic disorders in 2026, which could be a significant revenue driver if successful.
- Expansion of the Pipeline through Strategic Collaborations: iBio's strategic collaborations, such as the one with AstralBio, have been instrumental in expanding its pipeline. This collaboration has led to the discovery of novel targets, including an amylin receptor antibody, further diversifying iBio's therapeutic portfolio in cardiometabolic diseases. Such partnerships can generate collaboration revenue and provide additional product candidates for future development and commercialization.
- Launch of New Product Candidates, including Bispecific Antibodies: Beyond its lead candidates, iBio is actively developing new product modalities, notably a bispecific antibody program targeting myostatin/activin A. This program is also slated for clinical investigation in obesity and cardiometabolic disorders in 2026, representing a potential new class of therapies and a fresh avenue for revenue generation.
- Leveraging its AI-Driven Drug Discovery Platform: iBio's proprietary AI-driven drug discovery platform, which includes technologies like its Machine-Learning Antibody Engine, EngageTx, ShieldTx, StableHu, and AI epitope steering technology, is a core asset. This platform aims to accelerate the discovery and development of precision antibody therapies for various hard-to-treat diseases, including obesity and cancer, thereby continuously feeding its pipeline with new, innovative product opportunities that can drive long-term revenue growth.
AI Analysis | Feedback
Share Issuance
- In August 2025, iBio completed a public offering, generating initial gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses. The offering included pre-funded warrants and accompanying Series G and H warrants.
- If all Series G and Series H warrants issued in the August 2025 offering are exercised in full for cash, iBio could receive an additional $50 million in gross proceeds, potentially bringing the total gross proceeds to $100 million.
- In September 2025, iBio raised $6.2 million in gross proceeds through a warrant inducement transaction with institutional investors, which strengthened the company's balance sheet and provided additional working capital.
Inbound Investments
- In January 2025, iBio completed a private placement offering that raised over $650,000 from members of its Board of Directors and Officers.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 6.45 |
| Mkt Cap | 1.3 |
| Rev LTM | 39 |
| Op Inc LTM | -209 |
| FCF LTM | -120 |
| FCF 3Y Avg | -122 |
| CFO LTM | -78 |
| CFO 3Y Avg | -86 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 12.9% |
| Rev Chg 3Y Avg | 22.6% |
| Rev Chg Q | 27.3% |
| QoQ Delta Rev Chg LTM | 5.7% |
| Op Mgn LTM | -1,183.2% |
| Op Mgn 3Y Avg | -820.9% |
| QoQ Delta Op Mgn LTM | 58.7% |
| CFO/Rev LTM | -656.1% |
| CFO/Rev 3Y Avg | -451.0% |
| FCF/Rev LTM | -735.2% |
| FCF/Rev 3Y Avg | -552.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.3 |
| P/S | 33.9 |
| P/EBIT | -5.3 |
| P/E | -5.6 |
| P/CFO | -8.2 |
| Total Yield | -18.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -16.2% |
| D/E | 0.0 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -4.5% |
| 3M Rtn | 16.8% |
| 6M Rtn | 33.2% |
| 12M Rtn | -20.4% |
| 3Y Rtn | -56.6% |
| 1M Excs Rtn | -4.7% |
| 3M Excs Rtn | 6.2% |
| 6M Excs Rtn | 26.4% |
| 12M Excs Rtn | -32.9% |
| 3Y Excs Rtn | -124.4% |
Price Behavior
Price Behavior
| Market Price | $2.42 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 08/19/2008 | |
| Distance from 52W High | -62.2% | |
| 50 Days | 200 Days | |
| DMA Price | $2.00 | $1.17 |
| DMA Trend | down | up |
| Distance from DMA | 21.3% | 107.5% |
| 3M | 1YR | |
| Volatility | 166.4% | 140.2% |
| Downside Capture | -49.59 | 165.15 |
| Upside Capture | 281.24 | 101.87 |
| Correlation (SPY) | 18.0% | 17.0% |
IBIO Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.18 | 1.90 | 2.88 | 1.60 | 1.20 | 1.22 |
| Up Beta | 6.03 | 6.68 | 3.85 | 0.66 | 0.50 | 1.17 |
| Down Beta | -0.72 | 5.55 | 7.13 | 5.66 | 2.55 | 1.98 |
| Up Capture | 205% | 301% | 189% | 224% | 83% | 14% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 8 | 17 | 26 | 58 | 106 | 312 |
| Down Capture | 49% | -611% | 20% | -231% | 124% | 108% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 10 | 22 | 33 | 65 | 140 | 408 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IBIO | |
|---|---|---|---|---|
| IBIO | -33.0% | 140.2% | 0.41 | - |
| Sector ETF (XLV) | 7.7% | 17.3% | 0.27 | 20.9% |
| Equity (SPY) | 15.4% | 19.4% | 0.61 | 17.9% |
| Gold (GLD) | 73.9% | 24.8% | 2.19 | -3.2% |
| Commodities (DBC) | 8.9% | 16.6% | 0.34 | 4.2% |
| Real Estate (VNQ) | 4.6% | 16.5% | 0.10 | 19.3% |
| Bitcoin (BTCUSD) | -33.5% | 42.9% | -0.83 | 13.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IBIO | |
|---|---|---|---|---|
| IBIO | -70.0% | 153.9% | -0.17 | - |
| Sector ETF (XLV) | 8.1% | 14.5% | 0.37 | 12.1% |
| Equity (SPY) | 14.4% | 17.0% | 0.68 | 13.8% |
| Gold (GLD) | 21.4% | 16.9% | 1.03 | 2.8% |
| Commodities (DBC) | 11.5% | 18.9% | 0.49 | 2.0% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 13.0% |
| Bitcoin (BTCUSD) | 13.9% | 57.8% | 0.46 | 9.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IBIO | |
|---|---|---|---|---|
| IBIO | -51.2% | 155.6% | 0.12 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.54 | 4.9% |
| Equity (SPY) | 15.4% | 17.9% | 0.74 | 5.8% |
| Gold (GLD) | 15.7% | 15.5% | 0.84 | -1.0% |
| Commodities (DBC) | 8.0% | 17.6% | 0.37 | 0.1% |
| Real Estate (VNQ) | 6.0% | 20.7% | 0.25 | 3.3% |
| Bitcoin (BTCUSD) | 67.1% | 66.6% | 1.07 | 3.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | -8.0% | -12.8% | 46.4% |
| 8/18/2025 | -1.3% | 13.9% | 13.5% |
| 5/2/2025 | -1.9% | -19.4% | -20.3% |
| 2/10/2025 | -7.3% | 7.6% | 62.3% |
| 9/20/2024 | -6.1% | 5.6% | 56.9% |
| 5/13/2024 | 3.6% | 18.4% | 40.5% |
| 9/21/2023 | -1.6% | -11.3% | 1.6% |
| 9/27/2022 | -32.3% | -44.1% | -72.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 1 | 5 | 7 |
| # Negative | 13 | 9 | 7 |
| Median Positive | 3.6% | 7.6% | 40.5% |
| Median Negative | -7.0% | -13.3% | -21.9% |
| Max Positive | 3.6% | 18.4% | 62.3% |
| Max Negative | -32.3% | -44.1% | -72.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 09/05/2025 | 10-K |
| 03/31/2025 | 05/02/2025 | 10-Q |
| 12/31/2024 | 02/10/2025 | 10-Q |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 09/20/2024 | 10-K |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 02/09/2024 | 10-Q |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 09/27/2023 | 10-K |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 02/14/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 10/11/2022 | 10-K |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 02/14/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Duran, Felipe | Chief Financial Officer | Direct | Buy | 1132025 | 2.72 | 9,191 | 25,000 | 30,298 | Form |
| 2 | Brenner, Martin | See Remarks | Direct | Buy | 1132025 | 2.72 | 9,191 | 25,000 | 49,820 | Form |
| 3 | Banjak, Marc | Chief Legal Officer | Direct | Buy | 1132025 | 2.72 | 9,191 | 25,000 | 30,100 | Form |
| 4 | Arkowitz, David | Direct | Buy | 1132025 | 2.72 | 18,382 | 49,999 | 49,999 | Form | |
| 5 | Clark, William D | Direct | Buy | 1132025 | 2.72 | 1,838 | 4,999 | 4,999 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.